COVID-19-related thrombotic microangiopathy in a cirrhotic patient

Dig Liver Dis. 2020 Sep;52(9):946. doi: 10.1016/j.dld.2020.06.019. Epub 2020 Jun 15.

Authors

A Airoldi¹, G Perricone¹, S De Nicola², C Molisano³, P Tarsia⁴, L S Belli¹

Affiliations

¹ Hepatology and Gastroenterology Unit, ASST GOM Niguarda, Milano Italy.
² Hepatology and Gastroenterology Unit, ASST GOM Niguarda, Milano Italy. Electronic address: stella.denicola@ospedaleniguarda.it.
³ Internal Medicine Unit, Università di Milano Bicocca, Italy.
⁴ Pneumology Unit, ASST GOM Niguarda, Milano Italy.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acute Kidney Injury / etiology
Acute Kidney Injury / physiopathology*
Betacoronavirus
COVID-19
Coronavirus Infections / complications
Coronavirus Infections / physiopathology*
Disease Progression
Erythrocyte Transfusion
Factor Xa Inhibitors / adverse effects
Fibrin Fibrinogen Degradation Products / metabolism
Fondaparinux / adverse effects
Hematuria / etiology
Hematuria / physiopathology
Hematuria / therapy
Hepatorenal Syndrome / etiology
Hepatorenal Syndrome / physiopathology*
Humans
Liver Cirrhosis / complications
Liver Cirrhosis / physiopathology*
Male
Melena / etiology
Melena / physiopathology
Melena / therapy
Mesenteric Ischemia / drug therapy
Middle Aged
Pandemics
Platelet Transfusion
Pneumonia, Viral / complications
Pneumonia, Viral / physiopathology*
Portal Vein
Purpura / etiology
Purpura / physiopathology
Purpura / therapy
SARS-CoV-2
Severity of Illness Index
Thrombotic Microangiopathies / etiology
Thrombotic Microangiopathies / metabolism
Thrombotic Microangiopathies / physiopathology*
Thrombotic Microangiopathies / therapy

Substances

Factor Xa Inhibitors
Fibrin Fibrinogen Degradation Products
fibrin fragment D
Fondaparinux